Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2015

View Archived Issues

MaxCyte and Johns Hopkins University form CAR T-cell therapy immuno-oncology collaboration

TAS-4464, a new agent to treat multiple myeloma

E-selectin/CXCR4 dual antagonist shows antitumor activity

AACR and cancer charities fund DNA repair initiative against ovarian cancer

Astellas and Potenza Therapeutics to collaborate on immuno-oncology therapeutics

Icon Bioscience's extended-release dexamethasone reduces inflammation after cataract surgery

GenVec collaborates with LMIV on malaria vaccines

PPMD funds functional analysis of dystrophin spectrin-like repeats and effects of exon skipping

Anti-CD22-pyrrolobenzodiazepine ADC shows antitumor activity in vivo

Mission Therapeutics describes novel UCH-L1 inhibitors tested in vivo

Tolerability, activity of antibody-drug conjugate SAR-408701 encourage clinical development

First patient safety and pharmacokinetic data reported for LOXO-101

Capricor stem cell product given FDA orphan status for Duchenne muscular dystrophy

Cantrixil named orphan drug by FDA for ovarian cancer

SRX-1177 designated orphan drug in U.S. for metastatic melanoma

Ono Pharmaceutical requests squamous NSCLC indication for nivolumab

Phase I/IIa clinical trial initiated of dual FLT3/MEK inhibitor for hematologic malignancies

Post-hoc trial analyses enable Kamada to progress with inhaled AAT

FDA approves filgrastim for myelosuppression in acute radiation injury

Mnemosyne Pharmaceuticals discloses NR2A antagonists

Aurigene divulges PD-1 signaling pathway inhibitors

Trefoil Therapeutics patents modified FGFs

Canadian scientists describe novel lincRNAs and siRNAs

Dutrebis approved in E.U. for HIV-1 infection

Russian scientists present novel protein kinases inhibitors

OncoMed starts phase II trial of demcizumab in first-line metastatic pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...